🧔♂️ A friendly human may check it before it goes live. More news here
Indian home diagnostics firm Inito raises $29m series B
Inito, an India-based at-home diagnostics firm, has raised US$29 million in a series B round led by Bertelsmann India Investments and co-led by existing investor Fireside Ventures.
This brings Inito’s total equity funding to US$45 million.
The new funding will support the development of additional at-home diagnostic tests.
The company, which launched a fertility monitor in 2021, is expanding its platform to offer broader at-home hormone and health diagnostics using AI-engineered antibodies.
Inito’s fertility monitor enables users to measure hormone biomarkers such as FSH, estrogen, LH, and PdG at home.
Inito has teams in cities including Dubai, Bangalore, and London.
🔗 Source: Inito
🧠 Food for thought
Implications, context, and why it matters.
Telehealth and retail can play a larger role in at-home hormone testing
- Competitors such as Everlywell and LetsGetChecked include physician-reviewed results or clinician support 3. These offerings create room for platforms to bundle guidance and simplify payment flows.
- Hormone levels shift over days, so some kits need repeated testing, including Oova’s perimenopause kit; Oova is a home hormone testing startup 3. This pattern drives recurring fulfillment, which suits subscription partnerships with platforms like Inito for last-mile delivery.
- Retailers that target the 85% of women with menopause symptoms can offer in-store consultations to address accuracy worries with finger-prick tests 3. The service positions stores between full clinical lab testing and unsupported direct-to-consumer options 3.
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.